This brand name is authorized in Australia, New Zealand, Tunisia
The drug LOXALATE contains one active pharmaceutical ingredient (API):
|
1
Escitalopram
UNII 4O4S742ANY - ESCITALOPRAM
|
|
Escitalopram is a selective inhibitor of serotonin (5-HT) re-uptake with high affinity for the primary binding site. It also binds to an allosteric site on the serotonin transporter, with a 1000 fold lower affinity. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AB10 | Escitalopram | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AB Selective serotonin reuptake inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 8700X, 8701Y |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 12845, 12846 |
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 16583011, 16583012 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
